CAMILA ROCON DE LIMA ANDRETA
Projetos de Pesquisa
Unidades Organizacionais
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
conferenceObject Clinical, electrocardiographic, echocardiographic and cardiac magnetic resonance imaging follow-up in patients with non-compaction cardiomyopathy in isolation or in association with other diseases(2018) ROCON, C.; MELO, M. D. Tavares De; ARAUJO FILHO, J. A.; PARGA FILHO, J. R.; HAJJAR, L. A.; KALIL FILHO, R.; BOCCHI, E. A.; SALEMI, V. M.conferenceObject Biventricular imaging markers to predict outcome in non-compaction cardiomyopathy: a machine learning study(2018) ROCON, C.; TABASSIAN, M.; MELO, M. D. Tavares De; ARAUJO FILHO, J. A.; PARGA FILHO, J. R.; HAJJAR, L. A.; KALIL FILHO, R.; BOCCHI, E. A.; D'HOOGE, J.; SALEMI, V. M. C.- Noncompaction cardiomyopathy: a substrate for a thromboembolic event(2015) MELO, Marcelo Dantas Tavares de; ARAUJO FILHO, Jose Arimateia Batista de; PARGA FILHO, Jose Rodrigues; LIMA, Camila Rocon de; MADY, Charles; KALIL-FILHO, Roberto; SALEMI, Vera Maria CuryBackground: Noncompaction cardiomyopathy (NCC) is a rare genetic cardiomyopathy characterized by a thin, compacted epicardial layer and an extensive noncompacted endocardial layer. The clinical manifestations of this disease include ventricular arrhythmia, heart failure, and systemic thromboembolism. Case presentation: A 43-year-old male was anticoagulated by pulmonary thromboembolism for 1 year when he developed progressive dyspnea. Cardiovascular magnetic resonance imaging showed severe biventricular trabeculation with an ejection fraction of 15%, ratio of maximum noncompacted/compacted diastolic myocardial thickness of 3.2 and the presence of exuberant biventricular apical thrombus. Conclusion: Still under discussion is the issue of which patients and when they should be anticoagulated. It is generally recommended to those presenting ventricular systolic dysfunction, antecedent of systemic embolism, presence of cardiac thrombus and atrial fibrillation. In clinical practice the patients with NCC and ventricular dysfunction have been given oral anticoagulation, although there are no clinical trials showing the real safety and benefit of this treatment.